The text reads T1D RELAY a study for those newly diagnsoed with type 1 diabetes. Segments of light blue, dark blue and red lines run diagonally in the background.
Research Spotlight

Newly diagnosed with type 1 diabetes? Help us find out if a novel combination therapy can preserve insulin production

TrialNet’s latest clinical study will test two established immune therapies—rituximab-pvvr followed by abatacept—to see if the combination can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).

Read more
Raised hands appear from the bottom of the image with the text "HELP US STOP-T1D". The background of the image is pale green and contains Y-shaped autoantibodies arranged into the shape of a stop sign.
Research Spotlight

New prevention study now open for enrollment – Help us find out if a low dose immunotherapy can STOP-T1D

TrialNet researchers are testing low-dose anti-thymocyte globulin (ATG), an immunotherapy, to find out if it can delay or prevent type 1 diabetes (T1D) in people at high risk of clinical diagnosis (Stage 3) within two years. 

Read more
Subscribe to Research Spotlight